{"nctId":"NCT01528332","briefTitle":"Blue Light Device for Pain Therapy","startDateStruct":{"date":"2012-02"},"conditions":["Low Back Pain","Low Back Pain, Recurrent","Musculoskeletal Pain","Chronic Pain"],"count":171,"armGroups":[{"label":"Pain Relief Patch","type":"EXPERIMENTAL","interventionNames":["Device: Pain Relief Patch"]},{"label":"Control PRP device","type":"ACTIVE_COMPARATOR","interventionNames":["Device: Control PRP device"]}],"interventions":[{"name":"Pain Relief Patch","otherNames":["Blue light device, PRP patch, LED patch"]},{"name":"Control PRP device","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Is between 18 and 65 years of age, inclusive\n* Is able to consent to participation by signing the informed consent form\n* Has had localized mild to moderate (a score ≥ 2 and ≤ 6 on a 0 - 10 point pain intensity VAS) back pain for the 3 months prior to enrollment in study or longer\n* Has a mean pain intensity VAS value (calculated from pain intensity VAS at Screening Visit, home assessment and pretreatment at Visit 1) between ≥ 2 and ≤6 at baseline prior to randomization\n* Has skin type II, III or IV on the Fitzpatrick skin type scale (Types I - VI)\n* Is willing and able to adhere to all study requirements, including accurate completion of VAS and questionnaires at the required time points, and is willing and able to travel to investigator's site to attend all required visits\n* Is able to understand the study plan, its conditions, the therapy goals and expected outcomes\n\nExclusion Criteria:To be eligible for inclusion into this study, the patient must not meet any of the following criteria prior to enrollment:\n\nGeneral:\n\n* Is participating in another clinical study at time of this study, or has participated in another study within the 30 days prior to signing the informed consent form\n* Is pregnant or breast-feeding\n* Is a sexually active female of childbearing potential and is not using a medically approved form of contraception\n* Has moderate or severe arterial hypertension (WHO/ISH grade 2 or higher; systolic BP ≥ 160 and/or a diastolic BP ≥ 100), a history of stroke, myocardial infarction, angina pectoris, arteriosclerotic vascular disease (ASVD), or peripheral vascular disease, or (severe) congestive heart failure\n* Is in poor general health\n* Is an employee of the investigational site directly affiliated with this study and/or their immediate family members; an employee of the sponsor or the CRO\n\nBack Pain Related:\n\n* Has had any failed back surgery, or has had any surgery to torso, head or back within the previous 8 weeks\n* Had an acute dislocation or fracture within the previous 8 weeks\n* Has a degenerative central nervous system disease such as Multiple Sclerosis or Parkinson's disease; or a spinal stenosis that contributes to or is the cause of back pain; or Cauda equina syndrome, or other neurological symptoms indicating neuropathy\n* Has any sensory deprivation or diagnosis of shingles or postherpetic neuralgia (specifically in mid-trunk region)\n* Has wide spread pain\n* Has any inflammatory disease that causes pain or any other chronic disease or infection known to cause pain (e.g. spondyloarthropathy, rheumatoid arthritis, Lupus erythematodes, Lyme borreliosis, etc.)\n* Has schizophrenia, borderline syndrome or severe depression\n* Has or has had cancer\n* Has a history of severe osteoporosis (T score of 2.5 and a history of 1 or more bone fractures), or another severe bone disease\n* Is unwilling to abstain from other non-drug back pain treatments, such as massage, sauna, transcutaneous electrical nerve stimulation, etc., for the duration of the trial\n* Is unwilling to abstain from use of pain medication other than those recommended on steps 1 and 2 of the WHO Analgesic Ladder for the duration of the trial\n\nTreatment Related:\n\n* Has a known sun allergy, or known allergy to any device related material\n* Uses steroids or any photosensitizing medication\n* Has any known disease or idiopathic dermatosis such as porphyria, polymorphic light eruption, chronic actinic dermatitis, actinic prurigo or solar urticaria that causes photosensitivity\n* Has a skin pathology, tattoo etc., or skin disease such as local infection, psoriasis, eczema etc. in the treatment area\n* Has any anatomical pathology or other limitation that would prevent successful placement of the device\n* Has an implanted medical device (screw, etc.) in or near the treatment area or an active implantable medical device such as cardiac pacemaker, defibrillator, neurostimulator, cochlear implant, active drug administration device anywhere in the body\n* Is unwilling to abstain from sunbathing or use of tanning lights for the duration of the trial\n* Is in the process of seeking early retirement, or is engaged in outstanding litigation involving back pain","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"65 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change From Baseline (Mean of Three Measurements at Screening, Prior to Treatment Visit 1 and Treatment Visit 1 Pretreatment) in the Average Visual Analog Scale (VAS) Pain Intensity Over the 5 Treatment Days","description":"Pain intensity scored on a 10.0 cm VAS with the endpoints 0 = no pain; 10 = worst pain imaginable","paramType":"MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.24","spread":"0.11"},{"groupId":"OG001","value":"-0.87","spread":"0.11"}]}]}]},{"type":"SECONDARY","title":"Change From Baseline in Roland-Morris Disability Questionnaire (RMDQ) at Visit 5","description":"The RMDQ is a 24 list of yes/no questions about the effects of back pain on the participants daily activities. Each positive answer is a point; maximum total score = 24.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in VAS Pain Intensity at Follow up","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Treatment in VAS Pain Intensity at Follow up","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Baseline in RMDQ at Follow up","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Change From Treatment in RMDQ at Follow up","description":null,"paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Frequency, Severity, Nature and Duration of Adverse Events During the Whole Duration of the Study","description":"Adverse events will be assessed using descriptive statistical methods and compared between treatment arms.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Vital Sign Parameters","description":"Vital signs (blood pressure and pulse)will be assessed at each visit and changes from baseline compared between the treatment groups","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Changes From Baseline in Skin Condition","description":"Skin condition (erythema and hyperpigmentation as measured with the MX-18) and appearance (recorded with Polaroid photos) will be assessed once each at baseline and follow up, and before and after each treatment. The changes from baseline will be analysed using descriptive statistics and the two treatment arms compared.","paramType":null,"dispersionType":null,"classes":[]},{"type":"SECONDARY","title":"Average Visual Analog Scale Pain Relief Over 5 Treatments","description":"The average pain relief scored on a 10.0 cm VAS pain relief scale (endpoints 0 = no pain, 10 = no relief","paramType":null,"dispersionType":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":85},"commonTop":["Headache","General Disorders","Gastrointestinal disorders","Infections and Infestations","Ear and labyrinth disorders"]}}}